skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » UK Shares » Three Quick Facts » Three Quick Facts: Spire Healthcare, Nightcap and Immupharma

Here are three things you need to know in the financial markets this morning from investment writer, Tony Cross.

#1. Spire Healthcare signs another NHS support deal

Spire Healthcare [LON:SPI] has this morning announced that along with other private healthcare providers, it has reached an agreement in principal to support NHS England through the current COVID pandemic. The arrangement runs to the end of March and will be similar to a deal agreed in December 2020. This is likely to prove useful for the company, both when it comes to short term capital support and also in the longer term as it will have the potential to lead to higher demand once the impact of this wave of the pandemic is behind us.

Subscribe for more stories like this, 8am weekdays - for free!

#2. Nightcap investors will be raising a glass

Bar operator Nightcap [LON:NGHT] published a trading update this morning covering the 26 weeks to 26th December. Like for like sales were up by almost a quarter from the same period pre-pandemic, whilst once new bar openings are accounted for, that figure jumped to more than 46%. Stripping out the last two weeks of the reporting period – when “Plan B” Covid measures were in effect – offered an even more upbeat assessment of sales. The company is approaching one year since its IPO, has £9.4m cash at the bank and expects to see further estate expansion in the coming months.

#3. Immupharma notifies over stake

Pioneering drug developer Immupharma [LON:IMM] has published a TR-1 this morning advising that Alora Pharmaceuticals of Georgia, USA, has seen its stake in the company exceed 3%. The threshold was crossed just before Christmas so was likely triggered by the participation of Alora – a longstanding partner of the business – in December’s placing, which was undertaken at an 80% premium to the share price at the time.


This article is not investment advice. Investors should do their own research or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we follow most closely. They represent significant growth stories in our view. Our in-depth reports detail why we like them.


Subscribe for more stories like this, 8am weekdays - for free!

Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
Back To Top